Avadel Pharmaceuticals (AVDL) Operating Expenses: 2009-2021
Historic Operating Expenses for Avadel Pharmaceuticals (AVDL) over the last 12 years, with Dec 2021 value amounting to $23.1 million.
- Avadel Pharmaceuticals' Operating Expenses rose 62.24% to $23.1 million in Q4 2021 from the same period last year, while for Dec 2021 it was $85.5 million, marking a year-over-year increase of 417.86%. This contributed to the annual value of $85.5 million for FY2021, which is 417.86% up from last year.
- Avadel Pharmaceuticals' Operating Expenses amounted to $23.1 million in Q4 2021, which was down 9.85% from $25.7 million recorded in Q3 2021.
- Avadel Pharmaceuticals' 5-year Operating Expenses high stood at $96.3 million for Q4 2018, and its period low was -$30.2 million during Q2 2020.
- Moreover, its 3-year median value for Operating Expenses was $18.6 million (2019), whereas its average is $15.4 million.
- Its Operating Expenses has fluctuated over the past 5 years, first crashed by 237.14% in 2020, then surged by 172.69% in 2021.
- Quarterly analysis of 5 years shows Avadel Pharmaceuticals' Operating Expenses stood at $38.8 million in 2017, then skyrocketed by 148.10% to $96.3 million in 2018, then tumbled by 80.96% to $18.3 million in 2019, then decreased by 22.25% to $14.3 million in 2020, then surged by 62.24% to $23.1 million in 2021.
- Its Operating Expenses was $23.1 million in Q4 2021, compared to $25.7 million in Q3 2021 and $21.9 million in Q2 2021.